At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 44 enrolled
Drug / intervention
PTC-589drug
Likely dose
PTC-589 250 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2A Safety and Biomarker Study of EPI-589 in Mitochondrial Subtype and Idiopathic Parkinson's Disease Subjects
In Brief
A Phase 2 clinical trial evaluating PTC-589 for Parkinson's Disease. Completed, enrolled 44 participants across 5 sites in 3 countries.
Detailed Summary
Open-label study with 30-day run-in phase and adaptive design component to include more participants if deemed appropriate by investigators.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson's Disease
CountriesGermany, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJun 2015
Enrollment StartMay 2016
Primary CompletionJan 2019
TodayJul 2026
First PostedJun 4, 2015
Enrollment StartMay 17, 2016
Primary CompletionJan 8, 2019
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 11.1 years ago
Interventions
PTC-589drug
PTC-589 is a redox active molecule and will be provided in a 250 mg tablet formulation.